The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Abstract
Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.Methods In EMPOWER-Lung 1, a multicentre, open-label, global, phase 3 study, eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0-1; never-smokers were ineligible) were randomly assigned (1:1) to cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. Crossover from chemotherapy to cemiplimab was allowed following disease progression. Primary endpoints were overall survival and progression-free survival per masked independent review committee. Primary endpoints were assessed in the intention-to-treat population and in a prespecified PD-L1 of at least 50% population (per US Food and Drug Administration request to the sponsor), which consisted of patients with PD-L1 of at least 50% per 22C3 assay done according to instructions for use. Adverse events were assessed in all patients who received at least one dose of the assigned treatment. This study is registered with ClinicalTrials.gov, NCT03088540 and is ongoing.Findings Between June 27, 2017 and Feb 27, 2020, 710 patients were randomly assigned (intention-to-treat population). In the PD-L1 of at least 50% population, which consisted of 563 patients, median overall survival was not reached (95% CI 17·9-not evaluable) with cemiplimab (n=283) versus 14·2 months (11·2-17·5) with chemotherapy (n=280; hazard ratio [HR] 0·57 [0·42-0·77]; p=0·0002). Median progression-free survival was 8·2 months (6·1-8·8) with cemiplimab versus 5·7 months (4·5-6·2) with chemotherapy (HR 0·54 [0·43-0·68]; p<0·0001). Significant improvements in overall survival and progression-free survival were also observed with cemiplimab in the intention-to-treat population despite a high crossover rate (74%). Grade 3-4 treatment-emergent adverse events occurred in 98 (28%) of 355 patients treated with cemiplimab and 135 (39%) of 342 patients treated with chemotherapy.Interpretation Cemiplimab monotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%, providing a potential new treatment option for this patient population.Funding Regeneron Pharmaceuticals and Sanofi.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It may result in better OS and PFS compared to platinum-based chemotherapy in patients with advanced NSCLC, indicating a possible new treatment option for these patients [51].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [51]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Self-citationInterpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Cited by
Sorted by citations
Items 101–200 of 795
Chen, B., Yao, W., Li, X., Lin, G., Chu, Q., Liu, H., Du, Y., Lin, J., Duan, H., Wang, H., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02519-0 · Cited by 43
Li, Y., Sharma, A., & Schmidt‐Wolf, I. G. H. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01926-4 · Cited by 48
Liquid Biopsies in Lung Cancer
Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023) · Cancers · doi:10.3390/cancers15051430 · Cited by 42
Siciliano, M. A., Caridà, G., Ciliberto, D., D’Apolito, M., Pelaia, C., Caracciolo, D., Riillo, C., Correale, P., Galvano, A., Russo, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100465 · Cited by 42
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109638 · Cited by 45
Gridelli, C., Peters, S., Mok, T. S. K., Forde, P. M., Reck, M., Attili, I., & de Marinis, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100355 · Cited by 41
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 44
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 46
Vardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad670 · Cited by 40
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 44
Kılıçkap, S., Baramidze, A., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.033 · Cited by 39
Self-citationZhou, C., Li, M., Wang, Z., An, D., & Li, B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108353 · Cited by 41
Zhou, Y., Rassy, E., Coutté, A., Achkar, S., Espenel, S., Genestie, C., Pautier, P., Morice, P., Gouy, S., & Chargari, C. (2022) · Cancers · doi:10.3390/cancers14102449 · Cited by 39
Federico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 40
Sholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., & Li, W. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab027 · Cited by 40
Laguna, J. C., Tagliamento, M., Lambertini, M., Hiznay, J. M., & Mezquita, L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432488 · Cited by 40
Emerging role of circulating tumor cells in immunotherapy
Rzhevskiy, A. S., Kapitannikova, A. Y., Malinina, P., Volovetsky, A. B., Es, H. A., Kulasinghe, A., Thiery, J. P., Maslennikova, A., Zvyagin, A. V., & Warkiani, M. E. (2021) · Theranostics · doi:10.7150/thno.59677 · Cited by 39
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Xiong, A., Wang, J., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757993 · Cited by 38
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Ancel, J., Dormoy, V., Nawrocki‐Raby, B., Dalstein, V., Durlach, A., Dewolf, M., Gilles, C., Polette, M., & Deslée, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171649 · Cited by 36
Kuznik, A., Smare, C., Chen, C.-I., Venkatachalam, M., Keeping, S., Atsou, K., Xu, Y., Wilson, F. R., Guyot, P., Chan, K., et al. (2021) · Value in Health · doi:10.1016/j.jval.2021.08.009 · Cited by 36
Self-citationDuan, J., Zhang, Y., Chen, R., Liang, L., Huo, Y., Lü, S., Zhao, J., Hu, C., Sun, Y., Yang, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101302 · Cited by 35
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 39
Federico, A. D., Giglio, A. D., Parisi, C., Gelsomino, F., & Ardizzoni, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103302 · Cited by 34
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Zhang, K., Kong, X., Li, Y., Wang, Z., Zhang, L., & Xuan, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854967 · Cited by 34
Banna, G. L., Cantale, O., Muthuramalingam, S. R., Cave, J., Comins, C., Cortellini, A., Addeo, A., Signori, A., McKenzie, H., Escriu, C., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108985 · Cited by 34
Wang, Y., Kondrat, K., Adhikari, J., Nguyen, Q., Yu, Q., & Uprety, D. (2024) · Cancer · doi:10.1002/cncr.35476 · Cited by 33
Cortellini, A., Brunetti, L., Fazio, G. R. D., Garbo, E., Pinato, D. J., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010674 · Cited by 33
Passiglia, F., Galvano, A., Gristina, V., Barraco, N., Castiglia, M., Perez, A., Mantia, M. L., Russo, A. D., & Bazan, V. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-52 · Cited by 33
Kawachi, H., Yamada, T., Tamiya, M., Negi, Y., Gotô, Y., Nakao, A., Shiotsu, S., Tanimura, K., Takeda, T., Okada, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.22915 · Cited by 33
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 34
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 32
Rebuzzi, S. E., Prelaj, A., Friedlaender, A., Cortellini, A., Addeo, A., Genova, C., Naqash, A. R., Auclin, É., Mezquita, L., & Banna, G. L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103806 · Cited by 34
Oaknin, A., Monk, B. J., de Melo, A. C., Kim, H. S., Kim, Y. M., Lisyanskaya, A. S., Samouëlian, V., Lorusso, D., Damian, F., Chang, C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115146 · Cited by 31
Self-citationCirculating Biomarkers for Prediction of Immunotherapy Response in NSCLC
Goh, K. Y., Cheng, T. Y. D., Tham, S. C., & Lim, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020508 · Cited by 31
Reck, M., Popat, S., Grohé, C., Corral, J., Novello, S., Gottfried, M., Brueckl, W. M., Radonjic, D., Kaiser, R., & Heymach, J. V. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.009 · Cited by 32
Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
Zhang, H., Houadj, L., Wu, K. Y., & Tran, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14030336 · Cited by 34
Xiao, G., Liu, Z., Gao, X., Wang, H., Peng, H., Li, J., Yang, L., Duan, H., & Zhou, R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0262 · Cited by 32
Research progress of tumor targeted drug delivery based on PD-1/PD-L1
Liu, D., Gao, S., Zhai, Y., Yang, X., & Zhai, G. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121527 · Cited by 30
Alessi, J. V., Ricciuti, B., Wang, X., Pecci, F., Federico, A. D., Lamberti, G., Elkrief, A., Rodig, S. J., Lebow, E. S., Eicholz, J. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39874-8 · Cited by 32
Trestini, I., Belluomini, L., Dodi, A., Sposito, M., Caldart, A., Kadrija, D., Pasqualin, L., Riva, S. T., Scaglione, I. M., Tregnago, D., et al. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13568 · Cited by 29
Lavolé, A., Mazières, J., Schneider, S., Brosseau, S., Kiakouama, L., Greillier, L., Guihot, A., Abbar, B., Baron, M., Makinson, A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.031 · Cited by 29
Lin, E. P.-Y., Hsu, C., Berry, L. D., Bunn, P. A., & Shyr, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.27211 · Cited by 29
Wang, Y., Li, C., Wang, Z., Wang, Z., Wu, R., Wu, Y., Song, Y., & Liu, H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02580-1 · Cited by 29
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29
Gridelli, C., Peters, S., Velcheti, V., Attili, I., & de Marinis, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101192 · Cited by 30
Yao, J., Li, S., Bai, L., Chen, J., Ren, C., Liu, T., Qiu, J., & Dang, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103081 · Cited by 28
Self-citationZhang, X., Beachler, D. C., Masters, E. T., Liu, F., Yang, M., Dinh, J., Jamal‐Allial, A., Kolitsopoulos, F. M., & Lamy, F.-X. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.21216 · Cited by 29
Anobile, D. P., Salaroglio, I. C., Tabbò, F., Vecchia, S. L., Akman, M., Napoli, F., Bungaro, M., Benso, F., Aldieri, E., Bironzo, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3949 · Cited by 29
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 28
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01976-2 · Cited by 29
Vallejo, J. J., Singh, H., Larkins, E. A., Drezner, N. L., Ricciuti, B., Mishra-Kalyani, P. S., Tang, S. W., Beaver, J. A., & Awad, M. M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae006 · Cited by 27
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Versluis, J. M., Blankenstein, S. A., Dimitriadis, P., Wilmott, J. S., Elens, R., Blokx, W. A. M., van Houdt, W. J., Menzies, A. M., Schrage, Y. M., Wouters, M. W. J. M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008125 · Cited by 30
Guo, Y., Li, L.-H., Zheng, K., Du, J., Nie, J., Wang, Z., & Hao, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431150 · Cited by 28
Majem, M., Cobo, M., Isla, D., Márquez-Medina, D., Rodríguez‐Abreu, D., Casal‐Rubio, J., Morán, T., Bernabé, R., Pérez-Parente, D., Gracia, P. R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071365 · Cited by 28
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
Wang, C., Li, J., Zhang, Q., Wu, J., Xiao, Y., Song, L., Gong, H., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08662-2 · Cited by 27
Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
Khimani, K. S., Patel, S. P., Whyte, A., & Al-Zubidi, N. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806501 · Cited by 28
Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 28
Self-citationChallenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs
Gyawali, B., Carson, L. M., Berry, S. R., & de Moraes, F. Y. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100157 · Cited by 26
Tostivint, E. P., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03359-2 · Cited by 26
Rossi, A., Aimar, G., Audisio, M., Bungaro, M., Caglio, A., Liello, R. D., Gamba, T., Gargiulo, P., Ghisoni, E., Lombardi, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.008 · Cited by 27
Reck, M., Barlési, F., Yang, J. C.-H., Westeel, V., Felip, E., Özgüroğlu, M., Cobo, M., Sullivan, R., Kowalski, D. M., Andric, Z. G., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1445 · Cited by 27
Self-citationChen, J., Lee, T. H., Kuo, G. C., Yen, C., Lee, C., Chang, C., Tu, K., Chen, Y., Fang, J., Hung, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad292 · Cited by 26
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Frost, N., & Reck, M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432524 · Cited by 25
Zhang, X., Tian, D., Chen, Y., Chen, C., He, L.-N., Zhou, Y., Li, H., Lin, Z., Chen, T., Wang, Y., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-455 · Cited by 25
Self-citationHoltzman, L., Moskovitz, M. T., Urban, D., Nechushtan, H., Keren, S., Reinhorn, D. J., Wollner, M., Daher, S., Rottenberg, Y., Rovitzky, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.12.006 · Cited by 25
Velcheti, V., Hu, X., Li, Y., El-Osta, H. E., Pietanza, M. C., & Burke, T. A. (2022) · Cancers · doi:10.3390/cancers14041041 · Cited by 25
PD‐L1 immunohistochemistry: Clones, cutoffs, and controversies
Chebib, I. A., & Mino-Kenudson, M. A. (2022) · Apmis · doi:10.1111/apm.13223 · Cited by 25
New Immuno-oncology Targets and Resistance Mechanisms
Tokaz, M. C., Baik, C. S., Houghton, A. M., & Tseng, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01005-8 · Cited by 25
Cella, E., Zullo, L., Marconi, S., Rossi, G., Coco, S., Dellepiane, C., Alama, A., Rozeboom, L. M., Bennicelli, E., Parisi, F., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2116273 · Cited by 25
Zhao, Z., Zhang, W., Pang, L., Zeng, L., Liu, S., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166299 · Cited by 25
Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges
Mountzios, G., Naidoo, J., Wang, C., Creelan, B., Trotier, D., Campbell, T. C., & Peters, S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432526 · Cited by 24
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
Hektoen, H. H., Tsuruda, K. M., Fjellbirkeland, L., Nilssen, Y., Brustugun, O. T., & Andreassen, B. K. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02895-1 · Cited by 24
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Yan, Y., Cui, J., Fu, J., Su, Y.-J., Chen, X., Gu, Z., & Lin, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760737 · Cited by 24
de Mello, R. A., Voscaboinik, R., Luciano, J. V. P., Cremonese, R. V., Amaral, G. A., Castelo‐Branco, P., & Αντωνίου, Γ. (2021) · Cancers · doi:10.3390/cancers14010122 · Cited by 26
Pala, L., Sala, I., Oriecuia, C., Pas, T. M. D., Queirolo, P., Specchia, C., Cocorocchio, E., Ferrucci, P., Patanè, D. A., Saponara, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.26252 · Cited by 24
Ventura, D., Schindler, P., Masthoff, M., Görlich, D., Dittmann, M., Heindel, W. L., Schäfers, M. A., Lenz, G., Wardelmann, E., Möhr, M., et al. (2023) · Cancers · doi:10.3390/cancers15082297 · Cited by 24
Li, Y., Liang, X., Li, H., & Chen, X. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002750 · Cited by 26
Lin, X., Xie, M., Yao, J., Ma, X., Lin, Q., Zhang, X., Song, J., Bao, X., Zhang, X., Zhang, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1613 · Cited by 24
Ren, S., He, J., Fang, Y., Chen, G., Ma, Z., Chen, J., Guo, R., Lin, X., Yao, Y., Wu, G., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100312 · Cited by 24
Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043618 · Cited by 23
Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020
Debieuvre, D., Falchero, L., Molinier, O., Couraud, S., Cortot, A. B., Meyer, N., Asselain, B. J. R., Auvray, E., Templement-Grangerat, D., Bizieux, A., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2400443 · Cited by 23
Zhao, Y., Liu, L., & Weng, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714483 · Cited by 24
Liu, Q., Zhou, Z., Luo, X., Yi, L., Peng, L., Wan, X., Tan, C., & Zeng, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788569 · Cited by 23
Xiang, Z., Li, J., Zhang, Z., Cen, C., Chen, W., Jiang, B., Meng, Y., Wang, Y., Berglund, B., Zhai, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.883655 · Cited by 23
Cohen, I., Pareja, F. G., Socci, N. D., Shen, R., Doane, A. S., Schwartz, J., Khanin, R., Morris, E. A., Sutton, E. J., & Blasberg, R. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880959 · Cited by 24
Jin, Y., Li, H., Zhang, P., Yu, M., Zhang, H., & Li, X. (2023) · International Journal of Cancer · doi:10.1002/ijc.34427 · Cited by 23
Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
Montrone, M., Rosati, G., Longo, V., Catino, A., Massafra, R., Nardone, A., Pesola, F., Montagna, E. S., Marech, I., Pizzutilo, P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051833 · Cited by 23
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
Chen, L. N., Wei, A. Z., & Shu, C. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163798 · Cited by 23
Zhang, T., Forde, P. M., Sullivan, R. J., Sharon, E., Barksdale, E., Selig, W. K. D., Ebbinghaus, S., Fusaro, G., Günenç, D., Battle, D. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006555 · Cited by 23
Sereno, M., de Córdoba, I. H., Gutiérrez‐Gutiérrez, G., & Casado, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297988 · Cited by 23
Advances in Immunotherapy and Implications for Current Practice in Non–Small-Cell Lung Cancer
Steuer, C. E., & Ramalingam, S. S. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00305 · Cited by 23
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
Chiu, L., Lin, S., Lo, Y., Kuo, C. S., Yang, C., & Hsu, P. (2021) · Vaccines · doi:10.3390/vaccines9070689 · Cited by 23
Huang, Y., Cho, H. J., Stranger, B. E., & Huang, R. S. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-1013 · Cited by 23
Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
Goodman, D. (2022) · JPRAS Open · doi:10.1016/j.jpra.2022.06.003 · Cited by 22
Luo, X., Zhou, Z., Zeng, X., & Liu, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935581 · Cited by 22
Salifu, I., Singh, N., Berraondo, M., Remón, J., Salifu, S., Severson, E. A., Quintana, Á., Peiró, S., Ramkissoon, S. H., Vidal, L., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100713 · Cited by 22
Hu, X., Ren, J., Xue, Q., Luan, R., Ding, D., Tan, J., Su, X., & Yang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5570 · Cited by 22
Zheng, Z., Zhu, H., Fang, L., & Cai, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.996914 · Cited by 21
Metadata
- Authors
- Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Gao, B., Li, S., Lee, S., McGuire, K., Chen, C.-I., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D. M., Yancopoulos, G. D., Gullo, G., Lowy, I., & Rietschel, P.
- Affiliations
- Başkent University (TR)
- Istanbul Medeniyet University (TR)
- Dnipro State Medical University (UA)
- Istanbul University-Cerrahpaşa (TR)
- University of Wollongong (AU)
- Chulalongkorn University (TH)
- Columbia University Irving Medical Center (US)
- Regeneron (United States) (US)
- Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser (RU)
- Corresponding author
- Sezer, Ahmet
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 397
- Issue
- 10274
- Pages
- 592-604
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3129022890
- Cited by
- 789
- References
- 31
- Citations by year
- 2026: 52 · 2025: 133 · 2024: 164 · 2023: 197 · 2022: 167 · 2021: 74
- FWCI
- 54.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- cemiplimab, non-small cell lung cancer, PD-L1 expression, PD-1 inhibitors, first-line therapy, platinum-based chemotherapy, overall survival, progression-free survival, immune checkpoint inhibitors, treatment crossover, adverse events, immune-related adverse events, immunotherapy versus chemotherapy, never smokers
- MeSH terms
- Pemetrexed, Antineoplastic Agents, Immunological, Progression-Free Survival, Immune Checkpoint Inhibitors, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Rate, Carboplatin, Paclitaxel, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
